Welcome to our dedicated page for Endo International plc news (Ticker: ENDP), a resource for investors and traders seeking the latest updates and insights on Endo International plc stock.
Endo International plc (OTC: ENDPQ) is a leading specialty pharmaceutical company dedicated to improving the lives of patients through innovative and high-quality therapies. With a global team of passionate professionals, Endo transforms insights into effective treatments and ensures these are available to those who need them most.
Endo's core business revolves around the development, manufacturing, and marketing of branded and generic pharmaceutical products. The company focuses on areas such as pain management, urology, endocrinology, and oncology, catering to various unmet medical needs. Over the years, Endo has built a robust portfolio of products that enhance the quality of life for patients worldwide.
Recent Achievements and Projects:
- On September 21, 2023, Endo announced the presentation of data from clinical studies of collagenase clostridium histolyticum (CCH) for treating plantar fibromatosis at the American Orthopaedic Foot & Ankle Society's annual meeting. These studies showed improvement in nodule hardness and patient satisfaction, with a consistent safety profile.
- Endo has completed a Phase 2 study of CCH and anticipates beginning the pivotal Phase 3 program later this year. This effort underscores Endo's commitment to developing nonsurgical treatment options for conditions like plantar fibromatosis.
Endo's financial condition is currently under strategic restructuring, including Chapter 11 proceedings, aimed at addressing the company's liabilities and ensuring long-term viability. Despite these challenges, Endo continues to prioritize its mission of delivering life-enhancing therapies.
Endo's partnerships and collaborations play a crucial role in its success. By working with healthcare professionals, research institutions, and other industry stakeholders, Endo stays at the forefront of pharmaceutical innovation and effectively meets market demands.
For more information about Endo and its latest news, visit www.endo.com or connect with the company on LinkedIn.
BioSpecifics Technologies Corp. (NASDAQ: BSTC) has entered a definitive merger agreement for Endo International plc (NASDAQ: ENDP) to acquire BioSpecifics for approximately $658 million in equity value, translating to $88.50 per share. Both boards unanimously approved the transaction, expected to close in Q4 2020. Endo will launch an all-cash tender offer for all outstanding BioSpecifics shares, subject to conditions including majority share tendering and antitrust approvals. This acquisition builds on the existing collaboration between the companies in collagenase-based therapies.
Endo International plc (NASDAQ: ENDP) has announced an agreement to acquire BioSpecifics Technologies Corp. (NASDAQ: BSTC) for $88.50 per share, valuing the deal at approximately $540 million. This acquisition is set to enhance Endo's portfolio, particularly its collagenase-based therapies, including XIAFLEX and Qwo, which are positioned for long-term growth. The transaction is expected to close in late 2020 and has been unanimously approved by both companies' boards. Endo plans to fund the acquisition using cash on hand.
Endo International plc (NASDAQ:ENDP) announced that its Endo Aesthetics division will present data on Qwo™, a treatment for moderate to severe cellulite in adult women, at the American Society for Dermatologic Surgery's Annual Meeting from October 9-11, 2020. Key presentations include a survey on patient satisfaction and interim results on the treatment's effectiveness and safety for thigh cellulite. The data aims to provide insights on both the product's efficacy and patient retention strategies as Endo prepares for the product's launch in spring 2021.
Endo International plc (NASDAQ: ENDP) will report its third-quarter 2020 financial results on November 5, 2020, after market close. A conference call and webcast will follow on November 6, 2020, at 7:30 a.m. EST. Investors can access the call by dialing (866) 497-0462 (U.S./Canada) or (678) 509-7598 (International) with passcode 4073637. A replay will be available from November 6 at 10:30 a.m. ET until November 13. For more information, visit Endo's investor relations page.
Endo International plc (NASDAQ: ENDP) released its inaugural 2019 Corporate Responsibility Report, detailing its Environmental, Social, and Governance (ESG) initiatives. The report emphasizes Endo's commitment to ethics, accessibility of medicines, and diversity. It covers four areas: Business Practices, Team, Customers, and World, aimed at minimizing environmental impact and promoting responsible operations. The report is a foundation for future ESG efforts, with plans for annual updates. For the full report, visit Endo's website.
Endo International plc (NASDAQ: ENDP) has announced that its subsidiary, Par Pharmaceutical, has commenced shipping sapropterin dihydrochloride tablets and powder for oral solution after receiving FDA approval for its Abbreviated New Drug Application. These products are generic versions of Kuvan® and are the first generics available in the market. The sales of Kuvan® were approximately $489 million for the 12 months ending June 30, 2020. This launch expands Endo's product offerings, providing a more cost-effective alternative for patients.
Endo International plc (NASDAQ: ENDP) announced the presentation of data on Qwo™ (collagenase clostridium histolyticum-aaes), a treatment for moderate to severe cellulite in adult women, during the virtual Vegas Cosmetic Surgery & Aesthetic Dermatology (VCS) symposium from September 24-27, 2020. Key presentations include 'Injectable Cellulite Treatment' by Dr. Michael Gold, discussing trial data, and Dr. Sachin Shridharani's findings on Qwo's effects on tissue histology and injection site bruising. Qwo aims for a launch in spring 2021.
Endo International plc (NASDAQ: ENDP) will participate in the Citi 15th Annual BioPharma Virtual Conference from September 8-10, 2020. Management will host virtual meetings on September 10, 2020. Endo is a specialty pharmaceutical company focused on improving lives through quality therapies. Based in Dublin, Ireland, with U.S. headquarters in Malvern, Pennsylvania, Endo collaborates globally to develop life-enhancing treatments. More details can be found at www.endo.com.
Endo International plc (NASDAQ: ENDP) announced the results of its cash tender offer for its 5.75% Senior Notes due 2022. The offer expired on August 21, 2020, with approximately $10.43 million of the total $182.8 million in Notes validly tendered. Payments of $950 per $1,000 principal amount will be made on August 26, 2020, along with accrued interest. All purchased Notes will be retired. The announcement reinforces Endo's commitment to managing its debt effectively as part of its broader corporate strategy.
Endo International has initiated a cash tender offer for all outstanding 5.75% Senior Notes due 2022, amounting to $182.48 million. The offer, expiring on August 21, 2020, offers $950 for each $1,000 principal amount of notes tendered. Holders must submit their notes or a Notice of Guaranteed Delivery by the expiration time to qualify for the tender offer consideration, along with accrued interest from July 15, 2020. The expected payment date is August 26, 2020.
FAQ
What does Endo International plc do?
What recent achievements has Endo announced?
What are Endo's core therapeutic areas?
What is plantar fibromatosis?
What is Endo’s financial situation?
How is Endo addressing unmet medical needs?
Where can I find more information about Endo?
What is CCH and what is its significance?
Is CCH approved for treating plantar fibromatosis?
What partnerships does Endo engage in?
